0
Abstract: Slide Presentations |

CHANGES IN CLINICAL STATUS AND SERUM IGE LEVELS FOLLOWING SUBLINGUAL IMMUNOTHERAPY FOR 2 YEARS IN PATIENTS WITH ALLERGIC RHINITIS AND/OR ASTHMA DUE TO HOUSE DUST MITE FREE TO VIEW

Manimaran Marappan, MD*
Author and Funding Information

DD Hospital and Research Centre, Chennai, India


Chest


Chest. 2008;134(4_MeetingAbstracts):s43001. doi:10.1378/chest.134.4_MeetingAbstracts.s43001
Text Size: A A A
Published online

Abstract

PURPOSE:Sublingual Immunotherapy has been reported to be safe and effective in Allergic Rhinitis and Asthma.Purpose of this study is to Evaluate Clinical improvement and Changes in Serum IgE levels at the end of 2 Year course of Sublingual Immunotherapy against House Dust Mite.

METHODS:In a Double blind, placebo controlled trial, 62 patients suffering from clinically relevant Asthma and Allergic Rhinitis with Positive skin reactions to House Dust Mite and Elevated Total and Specific IgE underwent daily treatment with Sublingual Immunotherapy with Standardized extract of House Dust Mite for 2 years. Clinical symptom medication score and IgE levels were estimated after 2 years.

RESULTS:When comparing with the placebo, active group showed good improvement in clinical symptoms and signs.Specific and Total IgE levels showed significant reduction in active group while no change in control group.They were no drop outs.They were no significant side effects exept for minimal itching and burning sensation locally for first few days of immunotherapy.

CONCLUSION:Sublingual Immunotherapy seems to be very effective and well tolerated.Since compliance rate is very high and no side effects it can be preferred over Injection Immunotherapy.

CLINICAL IMPLICATIONS:Further studies are needed in a larger group of patients and long term studies in order to have an accurate results about the efficacy of Sublingual form of Immunotherapy. Also further and detailed immunological evaluation is necessary following Sublingual Immunotherapy.

DISCLOSURE:Manimaran Marappan, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, October 28, 2008

2:30 PM - 4:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543